CL2007001778A1 - Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a - Google Patents

Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a

Info

Publication number: CL2007001778A1
Authority: CL; Chile
Prior art keywords: pirazinacarboxamida; profilaxis; invested; agonists; antagonists
Prior art date: 2006-06-19

Application number

CL200701778A

Other languages

English (en)

Inventor

Hebeisen Hans Iding Matth Paul

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-19

Filing date

2007-06-18

Publication date

2008-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38616576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-18 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-05-23 Publication of CL2007001778A1 publication Critical patent/CL2007001778A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Addiction (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

CL200701778A 2006-06-19 2007-06-18 Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a CL2007001778A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06115646		2006-06-19

Publications (1)

Publication Number	Publication Date
CL2007001778A1 true CL2007001778A1 (es)	2008-05-23

Family

ID=38616576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200701778A CL2007001778A1 (es)	2006-06-19	2007-06-18	Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a

Country Status (20)

Country	Link
US (1)	US7629346B2 (es)
EP (1)	EP2035394B1 (es)
JP (1)	JP5139425B2 (es)
KR (1)	KR101084451B1 (es)
CN (1)	CN101460468B (es)
AR (1)	AR061486A1 (es)
AT (1)	ATE440090T1 (es)
AU (1)	AU2007263150B9 (es)
BR (1)	BRPI0713706A2 (es)
CA (1)	CA2654781A1 (es)
CL (1)	CL2007001778A1 (es)
DE (1)	DE602007002070D1 (es)
DK (1)	DK2035394T3 (es)
ES (1)	ES2329312T3 (es)
IL (1)	IL195422A (es)
MX (1)	MX2008015933A (es)
PL (1)	PL2035394T3 (es)
PT (1)	PT2035394E (es)
TW (1)	TW200815374A (es)
WO (1)	WO2007147746A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
ES2344128T3 (es)	2006-10-04	2010-08-18	F. Hoffmann-La Roche Ag	Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
AU2007304365A1 (en) *	2006-10-04	2008-04-10	F. Hoffmann-La Roche Ag	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) *	2008-02-07	2010-10-27	Sanofi-Aventis	Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US7897621B2 (en) *	2008-03-31	2011-03-01	Hoffmann-La Roche Inc.	2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) *	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
WO2010071837A1 (en)	2008-12-19	2010-06-24	Vertex Pharmaceuticals Incorporated	Pyrazine derivatives useful as inhibitors of atr kinase
PL2506716T3 (pl)	2009-12-01	2017-10-31	Abbvie Inc	Nowe związki tricykliczne
EP2569313A1 (en)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2011143425A2 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8962631B2 (en) *	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2012031817A1 (en)	2010-09-09	2012-03-15	F. Hoffmann-La Roche Ag	Determination of abca1 protein levels in cells
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CA2844865A1 (en) *	2011-09-12	2013-03-21	F. Hoffmann-La Roche Ag	3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
BR112014005637A2 (pt) *	2011-09-12	2017-03-28	Hoffmann La Roche	5-cicloalquila- ou 5-heterociclila-nicotinamidas
US9035053B2 (en)	2011-09-30	2015-05-19	Vertex Pharmaceuticals Incorporated	Processes for making compounds useful as inhibitors of ATR kinase
CA3089792C (en)	2011-09-30	2023-03-14	Vertex Pharmaceuticals Incorporated	Treating non-small cell lung cancer with atr inhibitors
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
LT2833973T (lt)	2012-04-05	2018-02-12	Vertex Pharmaceuticals Incorporated	Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas
US8999632B2 (en)	2012-10-04	2015-04-07	Vertex Pharmaceuticals Incorporated	Method for measuring ATR inhibition mediated increases in DNA damage
IN2015DN03145A (es) *	2012-12-07	2015-10-02	Hoffmann La Roche
CN103159687A (zh) *	2013-04-12	2013-06-19	苏州科捷生物医药有限公司	一种2-胺基吡嗪-5甲酸的合成方法
CN103467392B (zh) *	2013-10-09	2016-08-17	重庆工商大学	一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途
AU2016331955B2 (en)	2015-09-30	2022-07-21	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3940418A (en) *	1972-04-07	1976-02-24	G. D. Searle & Co.	Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
FR2713225B1 (fr)	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr)	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) *	1994-07-15	1997-01-21	Eli Lilly And Company	Cannabinoid receptor antagonists
FR2741621B1 (fr) *	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
ES2213892T3 (es)	1997-01-21	2004-09-01	Smithkline Beecham Corporation	Nuevos moduladores del receptor de canabinoides.
US5948777A (en)	1997-03-18	1999-09-07	Smithkline Beecham Corporation	Cannabinoid receptor agonists
FR2761265B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2783246B1 (fr)	1998-09-11	2000-11-17	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7393842B2 (en) *	2001-08-31	2008-07-01	University Of Connecticut	Pyrazole analogs acting on cannabinoid receptors
FR2800375B1 (fr)	1999-11-03	2004-07-23	Sanofi Synthelabo	Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6479479B2 (en) *	2000-03-03	2002-11-12	Aventis Pharma S.A.	Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6566356B2 (en) *	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) *	2000-03-03	2002-03-12	Aventis Pharma S.A.	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2805818B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
PT1268435E (pt)	2000-03-23	2007-02-28	Solvay Pharm Bv	Derivados de 4,5-diidro-1h-pirazol tendo actividade cb1-antagonista
FR2814678B1 (fr)	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) *	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US6509367B1 (en) *	2001-09-22	2003-01-21	Virginia Commonwealth University	Pyrazole cannabinoid agonist and antagonists
SE0104330D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104332D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
FR2838438A1 (fr)	2002-04-11	2003-10-17	Sanofi Synthelabo	Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
JP4041153B2 (ja)	2003-05-07	2008-01-30	ファイザー・プロダクツ・インク	カンナビノイド受容体リガンドとその使用
GB0314049D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
EP1641779A1 (en)	2003-06-18	2006-04-05	AstraZeneca AB	2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
US20040259887A1 (en) *	2003-06-18	2004-12-23	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
GB0314057D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314261D0 (en)	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
FR2856684B1 (fr) *	2003-06-26	2008-04-11	Sanofi Synthelabo	Derives de diphenylpyridine, leur preparation et leur application en therapeutique
PL1868999T3 (pl) *	2005-04-06	2009-12-31	Hoffmann La Roche	Pochodne pirydyno-3-karboksyamidu jako odwrotni agoniści CB1
WO2007011760A2 (en)	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
ES2344128T3 (es) *	2006-10-04	2010-08-18	F. Hoffmann-La Roche Ag	Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
US9130571B2 (en) *	2007-07-11	2015-09-08	Kyocera Corporation	Initializing a capacitive sensing switch for a wireless device

2007
- 2007-05-30 US US11/809,047 patent/US7629346B2/en not_active Expired - Fee Related
- 2007-06-11 BR BRPI0713706-0A patent/BRPI0713706A2/pt not_active IP Right Cessation
- 2007-06-11 AU AU2007263150A patent/AU2007263150B9/en not_active Ceased
- 2007-06-11 CN CN2007800208101A patent/CN101460468B/zh not_active Expired - Fee Related
- 2007-06-11 EP EP07765355A patent/EP2035394B1/en not_active Not-in-force
- 2007-06-11 JP JP2009515823A patent/JP5139425B2/ja not_active Expired - Fee Related
- 2007-06-11 MX MX2008015933A patent/MX2008015933A/es active IP Right Grant
- 2007-06-11 PL PL07765355T patent/PL2035394T3/pl unknown
- 2007-06-11 CA CA002654781A patent/CA2654781A1/en not_active Abandoned
- 2007-06-11 WO PCT/EP2007/055703 patent/WO2007147746A1/en active Application Filing
- 2007-06-11 PT PT07765355T patent/PT2035394E/pt unknown
- 2007-06-11 DE DE602007002070T patent/DE602007002070D1/de active Active
- 2007-06-11 KR KR1020087030952A patent/KR101084451B1/ko not_active IP Right Cessation
- 2007-06-11 DK DK07765355T patent/DK2035394T3/da active
- 2007-06-11 AT AT07765355T patent/ATE440090T1/de active
- 2007-06-11 ES ES07765355T patent/ES2329312T3/es active Active
- 2007-06-15 AR ARP070102647A patent/AR061486A1/es unknown
- 2007-06-15 TW TW096121665A patent/TW200815374A/zh unknown
- 2007-06-18 CL CL200701778A patent/CL2007001778A1/es unknown
2008
- 2008-11-20 IL IL195422A patent/IL195422A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
US7629346B2 (en)	2009-12-08
CA2654781A1 (en)	2007-12-27
EP2035394A1 (en)	2009-03-18
CN101460468A (zh)	2009-06-17
KR101084451B1 (ko)	2011-11-21
KR20090026294A (ko)	2009-03-12
MX2008015933A (es)	2009-01-13
AU2007263150B2 (en)	2012-05-17
JP5139425B2 (ja)	2013-02-06
IL195422A (en)	2012-06-28
CN101460468B (zh)	2012-05-30
US20070293509A1 (en)	2007-12-20
BRPI0713706A2 (pt)	2012-10-30
JP2009541247A (ja)	2009-11-26
AR061486A1 (es)	2008-08-27
TW200815374A (en)	2008-04-01
DK2035394T3 (da)	2009-10-05
ATE440090T1 (de)	2009-09-15
AU2007263150A1 (en)	2007-12-27
ES2329312T3 (es)	2009-11-24
WO2007147746A1 (en)	2007-12-27
PL2035394T3 (pl)	2010-01-29
PT2035394E (pt)	2009-10-13
IL195422A0 (en)	2009-08-03
EP2035394B1 (en)	2009-08-19
AU2007263150B9 (en)	2012-11-01
DE602007002070D1 (en)	2009-10-01

Publication	Publication Date	Title
CL2007001778A1 (es)	2008-05-23	Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a
CY2024007I1 (el)	2024-09-20	Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
HK1128471A1 (en)	2009-10-30	Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003176A1 (es)	2008-07-25	Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
IL198301A (en)	2013-06-27	Aryl amides are stored in thiazole and oxazole, a pharmaceutical preparation containing them and their use in the preparation of drugs
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
CL2007002972A1 (es)	2008-05-30	Compuestos derivados de imidazolona e imidazolidinona, inhibidores de la 11b-hsd1; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para el tratamiento y prevencion de diabetes, obesidad, trastornos alimentarios, disl
CL2007002841A1 (es)	2008-02-08	Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
WO2008021851A3 (en)	2008-06-26	Novel compounds as antagonists or inverse agonists for opioid receptors
BRPI0816553A2 (pt)	2017-07-18	"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
CL2007003440A1 (es)	2008-04-04	Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
IL193772A0 (en)	2009-08-03	4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
CL2007003100A1 (es)	2008-04-18	Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
IL192826A0 (en)	2009-02-11	Thiazole derivatives, their preparation and pharmaceutical compositions containing them
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
IL196136A (en)	2014-11-30	Its aminoindane or salt derivative, the pharmaceutical composition containing them and their uses
BRPI0816814A2 (pt)	2017-05-16	composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.